OMCL Stock Forecast 2025-2026
Distance to OMCL Price Targets
OMCL Price Momentum
10 Quality Stocks Worth Considering Now
Researching Omnicell (OMCL) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on OMCL and similar high-potential opportunities.
Latest OMCL Stock Price Targets & Analyst Predictions
Based on our analysis of 14 Wall Street analysts, OMCL has a neutral consensus with a median price target of $48.00 (ranging from $36.00 to $69.00). The overall analyst rating is Buy (7.6/10). Currently trading at $31.21, the median forecast implies a 53.8% upside. This outlook is supported by 4 Buy, 5 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Anne Samuel at JP Morgan, suggesting a 15.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
OMCL Analyst Ratings
OMCL Price Target Range
Latest OMCL Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for OMCL.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 17, 2025 | Wells Fargo | Stan Berenshteyn | Equal-Weight | Maintains | $38.00 |
| Mar 20, 2025 | JP Morgan | Anne Samuel | Neutral | Maintains | $36.00 |
| Feb 4, 2025 | Benchmark | Bill Sutherland | Buy | Maintains | $62.00 |
| Jan 13, 2025 | Wells Fargo | Stan Berenshteyn | Equal-Weight | Maintains | $40.00 |
| Jan 6, 2025 | B of A Securities | Allen Lutz | Neutral | Maintains | $46.00 |
| Nov 21, 2024 | JP Morgan | Anne Samuel | Neutral | Maintains | $44.00 |
| Oct 31, 2024 | Craig-Hallum | Matt Hewitt | Buy | Maintains | $64.00 |
| Oct 31, 2024 | Barclays | Stephanie Davis | Equal-Weight | Maintains | $58.00 |
| Oct 31, 2024 | B of A Securities | Allen Lutz | Neutral | Downgrade | $57.00 |
| Oct 14, 2024 | Wells Fargo | Stan Berenshteyn | Equal-Weight | Maintains | $41.00 |
| Oct 9, 2024 | Benchmark | Bill Sutherland | Buy | Reiterates | $48.00 |
| Aug 23, 2024 | JP Morgan | Anne Samuel | Neutral | Maintains | $37.00 |
| Aug 2, 2024 | Wells Fargo | Stan Berenshteyn | Equal-Weight | Maintains | $30.00 |
| Aug 2, 2024 | Barclays | Stephanie Davis | Equal-Weight | Upgrade | $39.00 |
| Aug 2, 2024 | B of A Securities | Allen Lutz | Buy | Maintains | $44.00 |
| Jul 15, 2024 | Benchmark | Bill Sutherland | Buy | Reiterates | $38.00 |
| May 3, 2024 | Benchmark | Bill Sutherland | Buy | Reiterates | $38.00 |
| Apr 30, 2024 | Benchmark | Bill Sutherland | Buy | Reiterates | $38.00 |
| Feb 9, 2024 | Wells Fargo | Stan Berenshteyn | Equal-Weight | Maintains | $26.00 |
| Feb 9, 2024 | Benchmark | Bill Sutherland | Buy | Maintains | $38.00 |
Omnicell Inc. (OMCL) Competitors
The following stocks are similar to Omnicell based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Omnicell Inc. (OMCL) Financial Data
Omnicell Inc. has a market capitalization of $1.44B with a P/E ratio of 113.7x. The company generates $1.11B in trailing twelve-month revenue with a 1.1% profit margin.
Revenue growth is +18.6% quarter-over-quarter, while maintaining an operating margin of +4.5% and return on equity of +1.0%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Omnicell Inc. (OMCL) Business Model
About Omnicell Inc.
Provides medication management solutions for healthcare.
Omnicell generates revenue by offering automated dispensing systems, pharmacy automation equipment, and software solutions to healthcare facilities. Their products help optimize medication management and supply chain processes, ultimately leading to improved safety and efficiency in hospitals and pharmacies.
The company utilizes advanced technologies, including robotics and cloud-based solutions, to enhance medication management practices. By addressing regulatory compliance and patient care challenges, Omnicell positions itself as a critical player in the healthcare sector, adapting to the evolving needs of its clients.
Company Information
Sector
Healthcare
Industry
Health Information Services
Employees
3,670
CEO
Mr. Randall A. Lipps
Country
United States
IPO Year
2001
Website
www.omnicell.comOmnicell Inc. (OMCL) Latest News & Analysis
Latest News
Zacks Premium research service offers Zacks Style Scores, aiding all types of investors—value, growth, or momentum—in identifying strong stocks.
Zacks Style Scores can enhance stock selection for various investment strategies, potentially leading to better returns and more informed decision-making for investors.
Zacks Style Scores help investors identify top-rated stocks aligned with their investing style, providing a useful tool for stock selection.
The Zacks Style Scores can help identify high-potential stocks tailored to specific investment strategies, enhancing portfolio performance and decision-making.
Omnicell has appointed Perry A. Genova, PhD, as its new Chief Technology Officer, which may impact the company's strategic direction and technological advancements.
Perry A. Genova's appointment as CTO may drive innovation and improve product offerings at Omnicell, potentially enhancing company growth and shareholder value.
Omnicell has announced a transition in its Chief Financial Officer position.
Leadership changes, especially in the CFO role, can impact a company's financial strategy and stability, potentially affecting stock performance and investor confidence.
OMCL's shares are up due to increased market acceptance of its XT Amplify program, although concerns remain regarding the unfavorable macroeconomic conditions.
OMCL's rising shares indicate strong market demand for its XT Amplify program, potentially boosting revenue. However, the unfavorable macroeconomic conditions could impact future growth and profitability.
OMCL is attracting investor attention due to its strong long-term growth strategy.
OMCL's long-term growth initiative signals potential for sustained revenue increases, attracting investor interest and possibly boosting stock performance.
Frequently Asked Questions About OMCL Stock
What is Omnicell Inc.'s (OMCL) stock forecast for 2025?
Based on our analysis of 14 Wall Street analysts, Omnicell Inc. (OMCL) has a median price target of $48.00. The highest price target is $69.00 and the lowest is $36.00.
Is OMCL stock a good investment in 2025?
According to current analyst ratings, OMCL has 4 Buy ratings, 5 Hold ratings, and 0 Sell ratings. The stock is currently trading at $31.21. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for OMCL stock?
Wall Street analysts predict OMCL stock could reach $48.00 in the next 12 months. This represents a 53.8% increase from the current price of $31.21. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Omnicell Inc.'s business model?
Omnicell generates revenue by offering automated dispensing systems, pharmacy automation equipment, and software solutions to healthcare facilities. Their products help optimize medication management and supply chain processes, ultimately leading to improved safety and efficiency in hospitals and pharmacies.
What is the highest forecasted price for OMCL Omnicell Inc.?
The highest price target for OMCL is $69.00 from at , which represents a 121.1% increase from the current price of $31.21.
What is the lowest forecasted price for OMCL Omnicell Inc.?
The lowest price target for OMCL is $36.00 from Anne Samuel at JP Morgan, which represents a 15.3% increase from the current price of $31.21.
What is the overall OMCL consensus from analysts for Omnicell Inc.?
The overall analyst consensus for OMCL is neutral. Out of 14 Wall Street analysts, 4 rate it as Buy, 5 as Hold, and 0 as Sell, with a median price target of $48.00.
How accurate are OMCL stock price projections?
Stock price projections, including those for Omnicell Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.